Novel lysine‐specific histone demethylase 1 inhibitor in acute myeloid leukaemia transformed from essential thrombocythaemia
Open Access
- 16 November 2021
- journal article
- case report
- Published by Wiley in Cancer Reports
- Vol. 5 (8) , e1588
Abstract
Background: While progress continues in the understanding of molecular abnormalities in acute myeloid leukaemia (AML), with some specific targeted therapies now available, it remains commonly fatal in the elderly. Leukaemic evolution and transformation from myeloproliferative neoplasms (MPN) may be associated with increased numbers of mutations in the genes associated with myeloid neoplasm and the prognosis in such patients is invariably dismal. Targeting of intracellular enzymes associated with integral cellular function has advanced understanding and promises improvements in treatments.Case: We report impressive prolonged response to therapy in a case of secondary AML, arising from essential thrombocythaemia (ET). The trial agent, the oral lysine‐specific histone demethylase 1 (LSD1) inhibitor Bomedemstat (IMG‐7289) was well tolerated. In addition to suppressing the malignant clone, these blasts showed differentiation to monocytes morphologically as well as by surface markers seen on flow cytometry. Bomedemstat has efficacy in the treatment of myelofibrosis and may have a special role in treatment of specific AML subtypes, including secondary leukaemias arising from MPN as seen.Conclusion: We report a case of an older adult with secondary AML transformed from ET, with a remarkable response to LSD1 inhibition with Bomedemstat, with prolonged reduction in blasts demonstrating differentiation to monocytes.Keywords
This publication has 14 references indexed in Scilit:
- Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic OptionsInternational Journal of Molecular Sciences, 2019
- LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AMLLeukemia, 2019
- Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all- trans retinoic acid in acute myeloid leukemia across subtypesHaematologica, 2018
- Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid LeukemiaFrontiers in Oncology, 2018
- LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease CloneHemaSphere, 2018
- Selective dissociation between LSD1 and GFI1B by a LSD1 inhibitor NCD38 induces the activation ofERGsuper-enhancer in erythroleukemia cellsOncotarget, 2018
- Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapyOncoTargets and Therapy, 2017
- Targeted deep sequencing in polycythemia vera and essential thrombocythemiaBlood Advances, 2016
- Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiationLeukemia, 2012
- The Outcomes and Costs of Acute Myeloid Leukemia Among the ElderlyArchives of internal medicine (1960), 2002